Clinical Trials Logo

Rheumatic Diseases clinical trials

View clinical trials related to Rheumatic Diseases.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06277635 Recruiting - Clinical trials for Rheumatoid Arthritis

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

To study the effect of silymarin against methotrexate-induced liver injury in rheumatic diseases including rheumatoid arthritis, psoriatric arthritis and psoriasis

NCT ID: NCT06263634 Recruiting - Psoriatic Arthritis Clinical Trials

Hand Exercises in Psoriatic Arthritis

Start date: April 5, 2023
Phase: N/A
Study type: Interventional

This study is a randomized controlled study examining the effects of 8-week hand home exercises on grip strength, functionality, disease activity and quality of life in patients with PsA. Individuals participating in the study will be randomly divided into 2 groups. Individuals in the intervention group will perform home exercises consisting of stretching, mobility and strengthening, 4 days a week for 8 weeks, and the patients' compliance with the exercise will be monitored by phone call once a week. Individuals in the control group are on the waiting list and the same home exercise program will be taught to the patients at the end of the study.

NCT ID: NCT06235710 Recruiting - Clinical trials for Rheumatoid Arthritis

Prevalence of Musculoskeletal Complaints in Nursing Home Residents

Start date: January 18, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to investigate the prevalence of joint complaints in nursing home residents with and without dementia. Primary objective: Number of tender or swollen joints. Secondary objectives: 1. Only when it is possible for the nursing home resident to provide us this information: how nursing home residents themselves assess the severity of their joint complaints that day (at that time). If the nursing home resident cannot answer this question (reliably), we use the Pain Assessment Checklist for Seniors with Severe Dementia (PACSLAC-D). 2. Investigate mobility limitations among nursing home residents. 3. To understand whether an accurate (differential) diagnosis for the joint complaints is reported in the electronic files. During the study, a standard physical examination of the musculoskeletal system will performed. Nursing home residents allocated in group 1 (no dementia) also provide an answer on 3 non-incriminating questions (severity of joint complaints, pain in general and general health). Nursing home residents allocated in group 2 (dementia) answer, if possible, 1 non-incriminating question (pain in joints at that moment). These question(s) and the physical examination are also widely used in daily clinical practice. No further incriminating questions or questionnaires will be administered. If the nursing home resident cannot answer this question (reliably), we use the PACSLAC-D.

NCT ID: NCT06233760 Recruiting - Rheumatic Diseases Clinical Trials

Prevalence of Abuse Among Patients With Rheumatic Diseases

Start date: April 1, 2023
Phase:
Study type: Observational

Patients with rheumatic diseases (RD) have a relevant representation in the adult population in Mexico. RD are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes. Regarding abuse in patients with RD, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability. The study aimed to identify the prevalence of abuse in patients with RD. The study will be conducted in two phases: the first one in which the GAS will be adapted for patients with RD, and this version will be validated in a population of our Institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with RD are explored.

NCT ID: NCT06227468 Recruiting - Healthy Clinical Trials

A Clinical Study to Map the HLA Genomic Region in the Greek Population

GENESIS
Start date: December 12, 2023
Phase:
Study type: Observational

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

NCT ID: NCT06226376 Recruiting - Fibromyalgia Clinical Trials

Mollii Suit and Fibromyalgia (EXOFIB 2)

Start date: January 8, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to demonstrate the improvement of fibromyalgia syndrome obtained following active stimulation compared to sham, with diminished functional disability and improved health status using Exopulse Molli suit stimulation. The main questions it aims to answer are: Evaluation of pain, fatigue, mood and quality of life changes observed after active stimulation in comparison to sham. Improvement of fibromyalgia syndrome as per the Fibromyalgia Impact Questionnaire (FIQ) Study subjects will participate in: A randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of "active" versus "sham" Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.

NCT ID: NCT06219551 Recruiting - Clinical trials for Tobacco Use Cessation

Smoking Cessation Support for Patients With Rheumatologic Diseases Via WhatsApp

Start date: November 10, 2023
Phase: N/A
Study type: Interventional

Smoking cessation support for patients with rheumatologist diseases is an underestimated issue. In the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. Among the willing group the highest quit rate was detected in the group that admitted to smoking cessation clinic. Therefore to increase the willingness to quit as well as to increase the Access to evidence based tobacco cessation support using new comminication technologies can be relevant. Investigators' aim in this study is to examine the effect of including WhatsApp in the routine smoking cessation practices on the quitting success of active smokers with rheumatic diseases who apply to the Rheumatology outpatient clinic.

NCT ID: NCT06018350 Recruiting - Clinical trials for Chronic Rheumatic Diseases

Medication Adherence in Rheumatic Diseases

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

The investigators will pilot test a clinician-led intervention to improve medication adherence in general rheumatology clinic across a spectrum of rheumatic diseases. The study will assess feasibility, acceptability, and fidelity, and explore signal for improved medication adherence.

NCT ID: NCT06004349 Recruiting - Autoimmune Disease Clinical Trials

Autoimmune and Autoinflammatory Genetics Study

Start date: April 15, 2022
Phase:
Study type: Observational

This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.

NCT ID: NCT05991219 Recruiting - Clinical trials for Rheumatic Heart Disease

Screening and Secondary Prevention Rheumatic Heart Disease Study

S2-RHD
Start date: September 26, 2022
Phase:
Study type: Observational

After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.